Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-13 combination study in advanced malignant solid tumors
CTR20243764Phase 2Active
- Sponsor
- Shanghai Yifeng Biotechnology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of K-13 in Nonhematologic neoplasms, sponsored by Shanghai Yifeng Biotechnology. Started Nov 2024; status: active.
02
Drugs
K-13
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243764.